Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab

Samsung Medical Center

Status: Completed

Conditions: Patients Treated With Rituximab-CHOP or Rituximab-CVP; Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT01311232

2010-11-035

Details and patient eligibility

About

This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy. Rituximab monoclonal antibody targeting CD20 induces B-cell depletion resulting in prolonged immune suppression. This leads to frequent reactivation of patients with a previous history of exposure to HBV or HBV carrier.

We collect the clinical features and laboratory findings of patients satisfied the inclusion criteria as follows.

1. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) or \ follicular B-cell lymphoma (FL).

2. Patients who had received at least two cycles of rituximab-CHOP or rituximab-CVP as a primary treatment

3. Patients with a history of previous exposure to HBV

   • HBV surface antigen (HBs Ag) positive Or
   • HBV core antibody (IgG anti-HBc antibody) positive

Then, we compare the HBV reactivation group with the control group (HBV reactivation does not happen) to find factors influencing HBV reactivation.

Full description

Description of factors associated with Hepatitis B virus reactivation:

• Laboratory parameters defining HBV status/activity at time of treatment initiation
• Lymphoma stage at rituximab treatment initiation (Ann Arbor, B-symptoms, bone marrow involvement, IPI, ECOG-score, LDH)
• Immunochemotherapy regimen (treatment line, rituximab dose and cycle)
• Disease status at time of HBV reactivation
• Antiviral prophylaxis (medication, dose, duration at time at time of reactivation)
• Patient demographics (age, gender, residence, ethnic origin, smoking status, alcohol consumption and occupation)

Time to Hepatitis B virus reactivation

• The time from start of rituximab-containing immunochemotherapy until first evidence of HBV reactivation meeting the criteria
• Description of prophylaxis and treatment with antiviral medication HBV vaccination Time of initiation of antiviral therapy of prophylaxis relating to clinical or laboratory signs of possible HBV reactivation Anti-viral medication used in prophylaxis or therapy
• Description of outcomes Outcomes of the HBV reactivation Outcomes of the rituximab-containing immunochemotherapy Demographics and previous infection history: Age, gender, nationality, race, social history, past medical history
• Parameters associated with lymphomas: Ann Arbor stage, number of extranodal involvement, serum LDH, serum β2-microglobulin, ECOG performance status, presence of B symptoms, International Prognostic Index, bone marrow invasion
• Laboratory parameters associated with hepatitis B virus:

hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti- HBs), hepatitis B e antigen (HBeAg), hepatitis B core antibody (anti-HBc), hepatitis B e antibody (anti-HBe), serum HBV DNA

• Lymphoma treatment history:

Line of treatment (first line, second line), rituximab and chemotherapy administration (dose, schedule), start date, last treatment date

• Prophylaxis or treatment against HBV reactivation:

antiviral drug (dose, schedule, duration)

• Hepatitis B virus reactivation:

onset, serologic markers, outcome

Enrollment: 600 estimated patients

Sex: All

Ages: 15 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

1. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) or follicular B-cell lymphoma (FL).

2. Patients who had received at least two cycles of rituximab-CHOP or rituximab-CVP as a primary treatment

3. Patients with a history of previous exposure to HBV

   • HBV surface antigen (HBs Ag) positive Or
   • HBV core antibody (IgG anti-HBc antibody) positive

4. Patients with documented HBV reactivation (definite or presumptive) occurring during treatment (at least two cycles of R-CHOP or R-CVP) or within 12 months after the last dose of rituximab

   • Definitive HBV reactivation

     • Elevation of serum HBV DNA level >1 log IU/mL from baseline or absolute increase of HBV DNA by 6 log10 IU/mL in HBsAg positive patients

   • Presumptive HBV reactivation - Increase of ALT (≥3x baseline value or absolute value of ≥100 U/L) and positive conversion of HBs Ag in previously HBsAg-negative patients

Exclusion Criteria:

1. Patients who had received chemotherapy other than R-CHOP or R-CVP after diagnosis
2. patients diagnosed with HIV, HCV or HDV co-infection
3. Patients who had undergone allogenic stem cell transplantation before hepatitis B virus reactivation was documented

Trial design

600 participants in 2 patient groups

Case

Description:

Patients with HBV reactivation

Control

Description:

Patients without HBV reactivation